Who Paid My Doc
A Randomized, Phase 2, Double-Blind Study to Evaluate the Efficacy of
Research payments
$700,931
Through program year 2024, $700,931 in research payments was reported against A Randomized, Phase 2, Double-Blind Study to Evaluate the Efficacy of, across 140 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $12,250 | 3 |
| 2023 | Research | $203,743 | 55 |
| 2022 | Research | $450,362 | 74 |
| 2021 | Research | $34,576 | 8 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
6 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.